Gastroesophageal Reflux Disease Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Gastroesophageal Reflux Disease Therapeutics Market is expected to grow at a CAGR of 2% during the forecast period 2022-2028.

Gastroesophageal reflux disease (GERD) is a digestive disorder caused by the reflux of stomach contents, such as stomach acid, food, and body fluids, into the esophagus. This causes irritation of the lining of the esophagus, resulting in the burning sensation the patient experiences. GERD is characterized by two main esophageal symptoms, including heartburn (reflux) and reflux. Also, if GERD is left untreated for a long time, it can cause inflammation of the esophagus, called esophagitis. It is associated with quality of life and poor sleep. Diagnosis is mainly performed using upper endoscopy, ambulatory acid (PH) probe, esophageal manometer, and X-ray. Although it can be managed with lifestyle changes and medication adjustments, some people may require strong medications or surgery. Common signs and symptoms of the disease include a burning sensation in the chest, difficulty swallowing, belching, epigastric pain, difficulty swallowing, reflux of food or sour fluid, and a feeling of a lump in the throat. Additionally, people with acid reflux at night may experience chronic cough, laryngitis, wheezing, sore throat or burning, worsening of asthma, and trouble sleeping. In addition, prolonged reflux can lead to strictures, esophagitis, and rarely metaplasia or cancer.

Market Segments

By Drug Class

• Antacids
• Proton Pump Inhibitors
  • Rabeprazole
  • Esomeprazole
  • Lansoprazole
  • Omeprazole
  • Pantoprazole
  • Dexlansoprazole
• Histamine-2 (H2) Blocker Receptor
  • Famotidine
  • Cimetidine
  • Ranitidine
• Dopamine Receptor Antagonist

Key Players

Major key players in the gastroesophageal reflux disease therapeutics market Merck Sharp & Dohme Pty Ltd., McNeil Consumer Pharmaceuticals Co., Amneal Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, Teva Pharmaceuticals USA, Inc., Takeda Pharmaceuticals America, Inc., Eisai R&D Management Co., Ltd, TWi Pharmaceuticals USA, Inc., Lannett    and Saol Therapeutics Inc.

Scope of the Report

The research study analyzes the global Gastroesophageal Reflux Disease Therapeutics industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Gastroesophageal Reflux Disease Therapeutics Market Report

1. What was the Gastroesophageal Reflux Disease Therapeutics Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Gastroesophageal Reflux Disease Therapeutics Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Gastroesophageal Reflux Disease Therapeutics Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.